Acctena's strategy is to bring selected drugs directly into phase 2 studies for new clinical use and expanded intellectual property

By evaluating study data and mechanism of action, experienced drug developers can identify diseases where these “abandoned” drugs can become beneficial medicines .

MESSAGE FROM OUR BOARD

"Acctena offers reduced risk for investors due to its diversified development portfolio consisting of drugs that have already been studied in man.

Kjell Stenberg
ACCTENA CEO & FOUNDER

Revive your clinical drug

Unlock the full potential of your abandonned clinical drug.
Apply for a chance to become part of Acctena's program.